Last reviewed · How we verify
Dexmetomidine 02
Dexmetomidine 02 is a Small molecule drug developed by Guangzhou General Hospital of Guangzhou Military Command. It is currently FDA-approved.
At a glance
| Generic name | Dexmetomidine 02 |
|---|---|
| Sponsor | Guangzhou General Hospital of Guangzhou Military Command |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmetomidine 02 CI brief — competitive landscape report
- Dexmetomidine 02 updates RSS · CI watch RSS
- Guangzhou General Hospital of Guangzhou Military Command portfolio CI
Frequently asked questions about Dexmetomidine 02
What is Dexmetomidine 02?
Dexmetomidine 02 is a Small molecule drug developed by Guangzhou General Hospital of Guangzhou Military Command.
Who makes Dexmetomidine 02?
Dexmetomidine 02 is developed and marketed by Guangzhou General Hospital of Guangzhou Military Command (see full Guangzhou General Hospital of Guangzhou Military Command pipeline at /company/guangzhou-general-hospital-of-guangzhou-military-command).
What development phase is Dexmetomidine 02 in?
Dexmetomidine 02 is FDA-approved (marketed).
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing